Compare Vanguard Total Stock Market Index Fund ETF (VTI) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total Stock Market Index Fund ETF vs Zimmer Biomet Holdings Inc — how do they compare? Vanguard Total Stock Market Index Fund ETF trades at $376.4, while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $18.05B). The key difference: Zimmer Biomet Holdings Inc pays a 1.01% dividend while Vanguard Total Stock Market Index Fund ETF pays none, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| VTI | ZBH | |
|---|---|---|
52-Week High | $384.30 | $104.26 |
52-Week Low | $311.68 | $79.58 |
Market Cap | — | $18.05B |
Sector | — | Health |
Enterprise Value | — | $25.11B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VTI trades at $377.60, down 0.56% with neutral technical signals. The ETF maintains broad U.S. market exposure across 3,515 stocks with a minimal 0.03% expense ratio. Recent institutional activity includes DMC Group's $794,000 investment in Q2 2026, while technical indicators show support at $375 and resistance at $379.
Long-term outlook remains positive given historical 10% annual market returns, though concentration risk exists with top ten holdings representing one-third of assets. Market sentiment favors VTI for diversification amid potential volatility, with analysts highlighting its core portfolio role for 20-year horizons.
ZBH trades at $94.22, down 3.93% on the day, with a bearish technical signal but oversold RSI readings. Recent earnings beats and raised 2026 guidance support fundamentals, with revenue growth and strong gross margins. Leadership promotions aim to accelerate commercial transformation, while cash flow trends show operational strength.
The stock offers upside to the $104.88 consensus target, but faces headwinds from debt levels and competitive pressures. Near-term support at $92 is critical; a hold rating aligns with mixed analyst views. Earnings execution and procedure demand growth are key catalysts for valuation expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
